The NPR Politics Podcast Abortion Status Quo Remains For Now After Supreme Court Punt
Jun 13, 2024
The Supreme Court recently ruled unanimously on the standing of plaintiffs challenging mifepristone regulations. This decision raises significant questions about abortion access and the FDA's role in drug approvals. Political implications are also explored, revealing a complex landscape for reproductive rights amidst ongoing legal battles. As states strategize to influence future court decisions, it’s clear that challenges to medication abortion access are far from over.
AI Snips
Chapters
Transcript
Episode notes
Unanimous Rejection Explained
- The Supreme Court unanimously rejected the challenge to mifepristone access due to lack of standing.
- The plaintiffs, mostly doctors who don't prescribe the drug, had no personal injury.
Mifepristone's Role
- Mifepristone is used in two-thirds of abortions in the US as part of a two-drug regimen.
- It has been FDA-approved since 2000, with over 5 million Americans having used it safely.
Status Quo Remains
- The Supreme Court's decision maintains the current patchwork system of abortion access.
- Mifepristone remains legally available where abortion isn't banned, but unavailable in 14 states.